Adenosine triphosphate
PreclinicalSmall molecule
Adenosine triphosphate is one of 20 small molecule programs targeting Paroxysmal atrial fibrillation. It is currently in Preclinical.
2
Indications
7
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Quietus
Merck & Co.Phase 3
Pulmicort
SSalix
Preclinical
NOC-110
NNocion Therapeutics
Phase 2
HS-10383
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
Iron Sulphate
PPierre Fabre Pharma GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Exercise Training1 trial
Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training
Withdrawn·—·Phase 1·NCT03972683
Diabetic Polyneuropathy1 trial
Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy
Not yet recruiting·EEgyptian International Pharmaceutical Industries Co·Phase 4·NCT07296354·200 enrolled
2 more indications
Patients With Advanced Solid Tumors1 trial
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00014248
Vasodilation1 trial
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults
Completed·—·Phase 1·NCT03738943·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adenosine triphosphate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details